Observational studyDevelopmental medicine and child neurology2026
Prevalence of spina bifida across the lifespan in the USA.
Observational study in Developmental medicine and child neurology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Folate deficiency disrupts key metabolic transitions within the developing neural ectoderm.bioRxiv : the preprint server for biology · 2026Article
- Shifting Burden of Neural Tube Defects from Early-Life Mortality to an Aging Population Living with Disability - China, 1990-2023.China CDC weekly · 2026Article
- Prevalence of spina bifida across the lifespan in the USA.Developmental medicine and child neurology · 2026Observational
- Using administrative healthcare databases to estimate the prevalence of spina bifida across the lifespan: Challenges and opportunities.Developmental medicine and child neurology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
aimTo estimate the prevalence of spina bifida across the lifespan, the number of people with spina bifida by state, and variations in spina bifida prevalence by insurance type, state, and selected demographics.
methodThis was an observational study that used administrative insurance data. We used three public-payer data sets (Medicaid Fee for Service, Medicare, and Medicare Advantage) and one large employer-sponsored insurance database (Health Care Cost Institute [HCCI]) to estimate all-age prevalence of spina bifida in the USA. Claims data from 2017 to 2019 were used to identify spina bifida based on International Classification of Diseases, 10th Revision codes.
resultsThe overall prevalence estimate of spina bifida was 3.20 per 10 000 (7.03 for Medicaid, 5.03 for Medicare, 1.72 for HCCI) and varied by demographics. We estimate at least 92 551 people in the USA live with spina bifida.
interpretationMost spina bifida prevalence estimates focus on birth prevalence. This study demonstrates that prevalence estimates across all ages throughout the lifespan can be generated using multiple insurance data sources.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.